Boston Healthcare Associates, Inc., Boston, Massachusetts, USA.
Renovia, Inc., Boston, Massachusetts, USA.
Neurourol Urodyn. 2022 Aug;41(6):1489-1497. doi: 10.1002/nau.24986. Epub 2022 Jun 22.
The objective of this analysis was to describe longitudinal adherence with recommended urinary incontinence (UI) evaluation and treatment guidelines over a 2-year period in patients newly diagnosed with stress (SUI) or mixed UI (MUI), and average 2-year cost associated with initial treatment.
A retrospective claims analysis using the IBM MarketScan database was conducted. Women diagnosed with SUI/MUI between July 1, 2014 and June 30, 2016 were identified using the International Classification of Diseases (ICD) 9 and 10 codes for SUI or MUI. Newly diagnosed SUI/MUI patients who did not have a UI-related diagnosis for at least 1 year before their index date were assessed.
103 813 patients with newly diagnosed SUI or MUI were identified. Of those, 96.15% (99 821/103 813) received an initial evaluation in accordance with professional guidelines (e.g., patient history, physical examination, urinalysis). Only 6.8% (5086/74 925) and 7.7% (2229/28 888) of patients with SUI and MUI, respectively, received a first-line behavioral treatment (e.g., pelvic floor muscle exercises, bladder training), according to guidelines. The 2-year average UI-related medical costs associated with guideline adherence for SUI were $5770.93 ± $9454.81 and for MUI, $4416.16 ± $7401.53. Nonadherence was observed in 59.2% (44 382/74 925) of SUI and 64.1% (18 530/28 888) of MUI patients. Two-year average UI-related medical costs for the nonadherent group were $8568.00 ± $11 275.52 for SUI and $6986.66 ± $10 765.55 for MUI, significantly more than the adherent group (p < 0.0001).
The majority of SUI or MUI patients do not receive a documented behavioral intervention as their first-line treatment, which is a recommendation by professional society guidelines. This was found to affect the cost burden for payers; those that were nonadherent had significantly higher costs 2-year postindex.
本分析的目的是描述新诊断为压力性尿失禁(SUI)或混合性尿失禁(MUI)的患者在 2 年内遵循推荐的尿失禁评估和治疗指南的纵向依从性,并评估与初始治疗相关的平均 2 年成本。
使用 IBM MarketScan 数据库进行回顾性索赔分析。使用 SUI 或 MUI 的国际疾病分类(ICD)第 9 或第 10 代码,确定 2014 年 7 月 1 日至 2016 年 6 月 30 日期间新诊断为 SUI/MUI 的女性。评估索引日期前至少 1 年没有尿失禁相关诊断的新诊断为 SUI/MUI 的患者。
共确定了 103813 例新诊断的 SUI 或 MUI 患者。其中,96.15%(99821/103813)按照专业指南(例如,患者病史、体格检查、尿液分析)进行了初始评估。仅有 6.8%(5086/74925)和 7.7%(2229/28888)的 SUI 和 MUI 患者分别根据指南接受了一线行为治疗(例如,盆底肌锻炼、膀胱训练)。SUI 遵循指南的 2 年平均与尿失禁相关的医疗费用为 5770.93 美元±9454.81 美元,MUI 为 4416.16 美元±7401.53 美元。SUI 患者中有 59.2%(44382/74925)和 MUI 患者中有 64.1%(18530/28888)不符合治疗规范。不符合治疗规范的患者组的 2 年平均与尿失禁相关的医疗费用为 SUI 组的 8568.00 美元±11275.52 美元,MUI 组的 6986.66 美元±10765.55 美元,显著高于符合治疗规范的患者组(p<0.0001)。
大多数 SUI 或 MUI 患者未接受作为一线治疗的记录在案的行为干预措施,这是专业协会指南的推荐意见。这会影响支付方的费用负担;不符合治疗规范的患者在索引后 2 年的费用显著更高。